Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...
Month: May 2023
SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
In study conducted for U.S. Army Medical Research Institute, SAB-183 demonstrated strong immune protection and response against Yersinia pestis infection,...
Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Conducted meetings with U.S. and select European regulatory agencies Received Notice of Exercise and upfront cash of $0.45 million from...
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
WALTHAM, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of...
Assure Holdings Corp. Announces Pricing of $6 Million Underwritten Public Offering
DENVER, May 12, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (NASDAQ: IONM) (“Assure Holdings” or the “Company”), a provider of...
Palisade Bio Reports First Quarter 2023 Financial Results
Company has sufficient cash expected to fund operations through 2024 Carlsbad, CA, May 12, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq:...
Freeline Completes ADS Ratio Change
LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the company’s previously disclosed...
Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage...
MediWound to Report First Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern TimeYAVNE, Israel, May 12, 2023 (GLOBE NEWSWIRE)...
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in...
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
Showcase to feature presentations by key opinion leaders Drs. Gaël Roué and Bhavana Pothuri Showcase to take place on May...
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the...
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and...
Evox Therapeutics Presents Progress Across its DeliverEX® Platform Highlighting Advances in Exosome-Mediated Delivery of Genetic Medicines Including Gene Editing and RNA Therapeutics
Six Upcoming Presentations at the Annual Meetings of the American Society of Gene and Cell Therapy (ASGCT) and of the...
Reflect Scientific Inc Reports First Quarter 2023 Results
OREM, Utah, May 12, 2023 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (OTCQB: RSCF), a provider of diverse products and services...
IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated...
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market
MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines...
Spectral Medical Announces First Quarter Results and Provides Corporate Update
New Trial Sites Enroll 60% of New Patient Enrollments Since the Beginning of April Tigris Patient Enrollment at 58 Patients...
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results
-- New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential...
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of up to $503 million and...